Dr Peter Tobin
is the APAC Medical Director of Oncology at Merck. Peter has worked in the
pharmaceutical industry in a variety of roles including communications, market
access, and medical affairs. He has worked on bringing new medicines to people
living with cancer including docetaxel, cabazitaxel, aflibercept, everolimus,
imatinib, octreotide LAR, ribociclib, cetuximab, and more recently avelumab. He
studied biochemistry and pharmacology at the University of Sydney and was
awarded the University Medal and first-class honours. He then completed a
Doctor of Philosophy (Medicine) at the University of Sydney. His thesis
focussed on how a better understanding of the metabolism of irinotecan could
improve its tolerability profile in patients with metastatic colorectal cancer.
He is currently completing a Masters of Business Administration at the
Macquarie Graduate School of Management.